.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
McKinsey
Merck
Cipla
Teva
Medtronic
Federal Trade Commission
Boehringer Ingelheim
Dow

Generated: July 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title: Salt of diclofenac with a pyrrolidine compound and pharmaceutical compositions which contain it
Abstract:The salt of diclofenac with a cyclic organic base is prepared by dissolving diclofenac in a suitable organic solvent, adding said cyclic organic base, reacting the two components together, removing the solvent and crystallizing the product obtained. Said salt is water soluble to an extent from 20% w/v to an extent exceeding 50% w/v, and is used to prepared pharmaceutical compositions preferably in granular form for use by dissolving in water for oral administration.
Inventor(s): Ziggiotti; Antonio (Vezia, CH), Di Schiena; Michele (Cisliano, IT)
Assignee: Altergon S. A. & Ricerfarma Srl. (IT)
Application Number:07/117,823
Patent Claim Types:
see list of patent claims
Compound; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Italy22320 A/86Nov 13, 1986

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria63304► Subscribe
Australia8117587► Subscribe
Canada1303050► Subscribe
Germany3769943► Subscribe
Denmark592987► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Farmers Insurance
Johnson and Johnson
Federal Trade Commission
McKinsey
Chubb
Dow
Healthtrust
UBS
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot